HBsAg Test (Hepatitis B Blood Tests)

Hepatitis B markers explained

Interpreting hepatitis B result patterns

Who should be tested for hepatitis B?

• People born in regions with high HBV prevalence (Asia, Africa, Eastern Europe)
• Household contacts or sexual partners of HBsAg-positive people
• People with multiple sexual partners
• Healthcare workers
• People with HIV or hepatitis C
• Pregnant women (all should be screened)
• People starting chemotherapy or other immunosuppressive treatment, since untreated HBV can reactivate under immune suppression³
• Children and adolescents born to a mother with chronic HBV infection²

Questions to ask your doctor

• Am I infected, immune, or susceptible?
• Do I need the hepatitis B vaccine?
• If I have chronic HBV, do I need antiviral treatment?
• Do I need regular liver ultrasound and AFP for liver cancer surveillance?

HBsAg vs anti-HBs vs anti-HBc vs HBV DNA: how they compare

“Hepatitis B test” is a panel of markers, each answering a different question:

The panel is read as a pattern: HBsAg positive means current infection; anti-HBs alone means vaccine protection; anti-HBc alone needs expert reading.

Reading your report: what your doctor actually looks at

When a doctor opens a hepatitis B result, no single marker stands alone. Here is the checklist they run through — and the same checklist helps you read your own report calmly:

1. Which markers are positive? The pattern across HBsAg, anti-HBs and anti-HBc is the diagnosis — one marker without the others is an incomplete picture.
2. Is it acute or chronic? Infection lasting beyond 6 months is chronic; IgM anti-HBc and the clinical story help date it. Most adult infections clear; most newborn infections become chronic — age at infection decides.
3. What is the viral load? A positive HBsAg leads to HBV DNA testing — the amount of virus guides monitoring and treatment decisions.
4. What is the liver doing? ALT, liver stiffness and ultrasound show whether the infection is damaging the liver — the virus count and the liver picture are followed together.
5. Who else needs testing? Household and sexual contacts, and newborns of positive mothers (who need vaccine plus immunoglobulin at birth) — hepatitis B is preventable, and contacts shouldn't wait.

A positive HBsAg is the start of a care pathway — viral load, liver assessment, family screening — not a verdict. Effective treatment exists for chronic infection. Discuss the full picture with your doctor.

Hepatitis B test price in India: typical bands across major lab chains

Hepatitis B markers are usually ordered as a panel; the vaccine itself is inexpensive and widely available. Typical list-price bands for panels:

These are approximate bands, not quotes: prices change often and vary by city, and home collection can add a small fee. Where possible, choose a NABL-accredited lab, and remember the reference range printed on your own report is the one that counts.

Frequently Asked Questions

Pharmacist's practical notes

Vaccination is the headline: hepatitis B is preventable, the vaccine is inexpensive and part of India's universal immunisation programme — yet adult catch-up vaccination remains patchy. If your household has a positive member and you were never vaccinated, that conversation is overdue.

A positive HBsAg changes prescribing: several medicines — including some immunosuppressants — can reactivate dormant hepatitis B, so the infection must be on your medication record permanently. Tell every new doctor and pharmacist; it changes what they can safely prescribe.

In India

In India, hepatitis B panels typically cost &rupee;800–1,500, varying by city and lab, and the vaccine is widely available and inexpensive — it is part of the universal immunisation programme, so most children born in recent decades are covered.

Where possible, choose a NABL-accredited lab. Given higher prevalence, family screening after a positive result is standard practice.

References

Sources cited on this page. PubMed links open the original abstract.

1. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. PMID 29405329 · doi:10.1002/hep.29800
2. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4(6):466–476. PMID 30982722 · doi:10.1016/S2468-1253(19)30042-1
3. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol. 2020;38(31):3698–3715. PMID 32716741 · doi:10.1200/JCO.20.01757

The hepatitis B serology puzzle, what each marker means

Hepatitis B has more serological markers than virtually any other infection, and interpreting them requires understanding what each marker represents in the viral life cycle:

• HBsAg (hepatitis B surface antigen): The virus's outer coat protein. Its presence in blood means the person is currently infected with hepatitis B, either acutely or as a chronic carrier. Persisting beyond 6 months defines chronic hepatitis B.
• Anti-HBs (antibody to HBsAg): Protective antibody. Present after successful vaccination (as the sole positive marker), or after natural infection and recovery (alongside anti-HBc). Anti-HBs above 10 mIU/mL indicates immunity.
• HBeAg (hepatitis B e-antigen): A secreted protein indicating active viral replication. HBeAg-positive chronic hepatitis B is highly infectious (serum HBV DNA typically very high) and causes more aggressive liver disease. Spontaneous HBeAg seroconversion to anti-HBe is a favourable event indicating reduction of viral replication.
• Anti-HBc (antibody to core antigen): IgM anti-HBc rises in acute infection; IgG anti-HBc persists for life and indicates past or current infection. Anti-HBc IgG positive with negative HBsAg and positive anti-HBs = resolved infection (immune). Anti-HBc IgG with negative HBsAg and negative anti-HBs = "occult" hepatitis B, low-level infection sometimes reactivated by immunosuppression.
• HBV DNA (viral load): Quantitative PCR measurement of virus in the blood. The key test for guiding treatment decisions. HBV DNA above 2000 IU/mL is the threshold above which antiviral therapy is generally considered in chronic hepatitis B with evidence of liver damage.

Chronic hepatitis B, monitoring and treatment

Chronic hepatitis B does not mean severe liver disease is inevitable. Many people have "inactive" chronic infection, normal ALT, HBV DNA below 2000 IU/mL, and minimal liver fibrosis, and can be monitored without treatment. Key monitoring schedule includes: ALT every 6 months, HBV DNA every 6–12 months, and abdominal ultrasound plus AFP (alpha-fetoprotein) every 6 months for hepatocellular carcinoma (HCC) surveillance, because HBV-related HCC can develop even without cirrhosis, unlike most other causes of liver cirrhosis. Tenofovir and entecavir are first-line antiviral agents, they suppress HBV DNA to undetectable levels, normalize ALT, and significantly reduce the risk of cirrhosis progression and HCC.